Denmark’s decentralized AF trial puts sleep apnea screening into the home
Obstructive sleep apnoea has long sat in the background of atrial fibrillation care: common, modifiable, and frequently missed. VIR-SAAF moves that problem out of the clinic and into the patient’s home, asking a direct question with practical consequences for everyday rhythm management — does systematic screening for sleep-disordered breathing change how people with atrial fibrillation feel and function over time?
The trial is built around a simple but consequential gap in care. Guidelines already support considering OSA assessment in AF, yet screening remains inconsistent, and treatment pathways are often fragmented. In many patients, nocturnal hypoxia, repeated arousals, and sympathetic surges may feed atrial remodeling, blood pressure variability, and autonomic instability, all of which can make AF more persistent and harder to control. If identifying OSA earlier changes those downstream forces, the effect should be visible not only in sleep metrics but in symptoms, daily activity, and patient-reported quality of life.
A fully remote trial architecture changes who can be reached
VIR-SAAF is a national, investigator-initiated, decentralized randomized clinical trial enrolling adults with paroxysmal or persistent AF across Denmark. Participants are randomized 2:1 to home-based screening for OSA or to no screening, with the entire study conducted remotely through a purpose-built mobile application. Electronic consent, digital questionnaires, rhythm monitoring, activity tracking, and real-time communication with investigators are all handled without in-person visits.
The design matters because sleep apnea screening has often been limited by logistics rather than biology. In routine practice, patients may need to travel for testing, coordinate appointments around work or caregiving, and navigate multiple specialty referrals before any actionable diagnosis emerges. A home-based workflow lowers those barriers and may capture a broader AF population, including people who would otherwise never enter a sleep laboratory or clinic-based screening pathway. It also reflects how AF care is increasingly delivered: dispersed, digital, and dependent on patient engagement outside traditional hospital walls.
One sentence captures the trial’s ambition cleanly: VIR-SAAF is testing screening itself as the intervention.
Quality of life is the primary endpoint because symptoms drive care
The primary outcome is the between-group difference in change from baseline to 18 weeks in quality of life, measured with the Atrial Fibrillation Effect on QualiTy-of-life questionnaire. That choice is clinically grounded. For many people with AF, the burden of disease is not only stroke risk or arrhythmia recurrence, but fatigue, reduced exercise tolerance, sleep disruption, and the constant unpredictability of palpitations. A screening strategy that identifies untreated OSA but fails to improve those daily realities would have limited value, even if it increases diagnosis rates.
An 18-week window is short enough to capture early shifts in symptoms and engagement, yet long enough to see whether referral after screening changes the lived experience of AF. If screening uncovers OSA and prompts treatment, the resulting reduction in nocturnal obstruction and intermittent hypoxemia could improve daytime alertness and physical functioning before any structural cardiac remodeling becomes measurable. In that sense, the endpoint is tightly aligned with a plausible biological pathway: better sleep continuity may translate into better autonomic balance, less symptom amplification, and more stable rhythm-related well-being.
Remote monitoring links sleep apnea detection to activity and AF outcomes
The protocol also includes physical activity and AF-related outcomes, giving the trial a broader clinical frame than a pure diagnostic study. That is important because sleep apnea can influence more than arrhythmia burden. Fragmented sleep and hypoxemia can sap activity levels, while untreated OSA may contribute to blood pressure elevation, atrial stretch, and a more arrhythmogenic substrate. If home screening identifies patients whose functional limitations are partly sleep-driven, changes may appear in activity tracking alongside quality-of-life scores.
The use of a mobile application is more than a convenience feature. It creates a continuous data stream that can support adherence, follow-up, and communication across a geographically distributed cohort. In a condition like AF, where patients often move between primary care, cardiology, and sleep medicine, fragmented documentation can obscure the connection between symptoms and underlying sleep pathology. VIR-SAAF tries to close that gap by embedding the study in daily life rather than asking participants to enter a research center repeatedly.
Why screening the right patients could alter AF care
The biological rationale for screening is strong even before the trial reports results. OSA can intensify nocturnal swings in intrathoracic pressure, drive intermittent oxygen desaturation, and increase sympathetic activation. Those stresses can encourage atrial remodeling and make AF harder to suppress. If home screening routes patients toward evaluation and treatment sooner, it may identify a reversible contributor to AF burden that would otherwise stay hidden beneath antiarrhythmic drug use, rate control, or ablation planning.
The trial also addresses a real clinical uncertainty: whether screening alone, without a traditional clinic-based pathway, can produce measurable patient benefit. The answer has practical implications for cardiology services that already face long wait times and limited access to polysomnography. A positive result would support a scalable model in which AF clinics use digital tools to uncover sleep apnea earlier and at lower logistical cost. A neutral result would still be informative, because it would suggest that detection must be paired with a different intensity of follow-up, treatment uptake, or patient selection to move patient-centered outcomes.
Ethics approval and dissemination are already in place
The study has received approval from the Danish National Committee on Health Research Ethics, and all participants provide electronic informed consent before enrolment. Results are slated for peer-reviewed publication and presentation at national and international scientific meetings.
VIR-SAAF is registered as NCT06618417. Its most important limitation is also its most important uncertainty: the protocol can define whether decentralized screening is feasible and clinically meaningful, but only the completed trial can show whether home-based OSA detection changes quality of life enough to justify adoption as a routine part of AF care.